PRospective tumor sampling in oncology patients with solid tumors treated with Immune Modulating Agents

• Conditions: solid malgnancies; solid tumors; 10038666

• Registration Number: NL-OMON54892
• Lead Sponsor: Erasmus MC, Universitair Medisch Centrum Rotterdam

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 15 April 2024

Recruitment & Eligibility

• Status: Pending
• Sex: Not specified
• Target Recruitment: 350

Inclusion Criteria

• Histological or cytological proven solid tumor
• Age >=18 years
• Written informed consent
• Performance score: WHO 0-2 at the time of study entry
• Planned treatment with (intravenous) immune modulating agents for any type of
cancer according to standard of care.

Exclusion Criteria

• Unable to draw blood for study purposes (e.g. severe anemia Hb <5,5 mmol/L)
• Unable to safely obtain tumor biopsies
• Known human immunodeficiency virus (HIV), chronic hepatitis B or C infection

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>The primary study endpoint is the evaluation of the interaction between genetic<br /><br>and immunological characteristics of a patients tumor and the IMA prescribed.</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Secondary endpoint includes the determination of immunological and genetic<br /><br>differences in tumor biopsies of patients responding and patients not<br /><br>responding to IMA. </p><br>